SEC Filings Reveal GlaxoSmithKline's 13% Stake in This Massachusetts Biotech Post author:Sam Post published:November 16, 2017 Post category:BioPharma A filing with the SEC indicates that Glaxo now has a 13 percent stake in Spero Therapeutics. Source: BioSpace You Might Also Like Gilead Elated as the FDA OKs New Blockbuster HIV Pill Biktarvy February 7, 2018 Germany's Fresenius Kabi AG Slams Down $4.3 Billion for Akorn in U.S. Expansion April 24, 2017 3 High-Risk Biotechs That Could Pop or Drop in 2018 February 4, 2018